Director, Head of Animal Science & TechnologiesJoin to apply for the Director, Head of Animal Science & Technologies role at Fusion Pharmaceuticals.
Base pay rangeCA$156,758.40/yr - CA$235,137.60/yr
Fusion Pharmaceuticals, a member of the AstraZeneca Group,
is a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical portfolio includes but is not limited to: FPI-2265 targeting PSMA for metastatic castration resistant prostate cancer currently in a Phase 2 trial;

FPI-1434 targeting IGF-1R currently in a Phase 1 trial;

and FPI-2068, a bispecific IgG-based EGFR-cMET targeted radioconjugate currently in a Phase 1 trial. Fusion has multiple other pipeline programs that will soon be entering into early FIH trials. In addition, Fusion...